Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03762850 · ClinicalTrials.gov registry record · Phase 3

A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy

A Phase 3 study of Immunoglobulin A Nephropathy, sponsored by Travere Therapeutics.

Active
Registry status
Phase 3
Development phase
406
Enrollment target
20
Study locations

NCT03762850 is a Phase 3 study of Immunoglobulin A Nephropathy that is active but no longer recruiting, run by Travere Therapeutics. The registered enrollment target is 406 participants, above the 273-participant average among 13 other Immunoglobulin A Nephropathy trials with a reported enrollment target (49% higher). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03762850, a Phase 3 study of Immunoglobulin A Nephropathy, is active but no longer recruiting, sponsored by Travere Therapeutics.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
406 participants
Enrollment target
20
Study locations

Study Summary

To determine the long-term (approximately 2 years) nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with immunoglobulin A nephropathy (IgAN).

Conditions Studied

Immunoglobulin A Nephropathy

Interventions

  • DRUG Dapagliflozin
  • DRUG sparsentan
  • DRUG irbesartan

Study Locations (20)

California

  • Travere Investigational Site - Glendale
  • Travere Investigational Site - Montebello
  • Travere Investigational Site - Northridge
  • Travere Investigational Site - San Diego
  • Travere Investigational Site - San Diego
  • Travere Investigational Site - Stanford

Florida

  • Travere Investigational Site - Coral Springs
  • Travere Investigational Site - Hollywood
  • Travere Investigational Site - Miami
  • Travere Investigational Site - Miami
  • Travere Investigational Site - Winter Park

Alabama

  • Travere Investigational Site - Birmingham
  • Travere Investigational Site - Homewood

Colorado

  • Travere Investigational Site - Denver

Georgia

  • Travere Investigational Site - Lawrenceville

Idaho

  • Travere Investigational Site - Nampa

Illinois

  • Travere Investigational Site - Hinsdale

Indiana

  • Travere Investigational Site - Muncie

Trial Details

FieldValue
Enrollment Target 406 participants
Start Date 2018-12-11
Est. Completion 2026-07
Phase Phase 3

Sponsor

Travere Therapeutics

12 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03762850

The ClinicalTrials.gov registry entry for NCT03762850 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 406 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 273-participant average among 13 other Immunoglobulin A Nephropathy trials with a reported enrollment target (49% higher). The listed sponsor is Travere Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Immunoglobulin A Nephropathy appearing as the primary indexed condition, and to 3 interventions - of which Dapagliflozin is the first listed.

NCT03762850 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Alabama.

Frequently Asked Questions

What is clinical trial NCT03762850 about?

NCT03762850 is a clinical study titled "A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy". To determine the long-term (approximately 2 years) nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with immunoglobulin A nephropathy (IgAN).

What is the current status of trial NCT03762850?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 406 participants. The study started on 2018-12-11. Estimated completion is 2026-07.

What conditions does trial NCT03762850 study?

This clinical trial studies the following conditions: Immunoglobulin A Nephropathy.

What interventions are being tested in trial NCT03762850?

The interventions under investigation include: Dapagliflozin (DRUG), sparsentan (DRUG), irbesartan (DRUG).

Who is sponsoring clinical trial NCT03762850?

This trial is sponsored by Travere Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03762850 being conducted?

This trial has 20 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Immunoglobulin A Nephropathy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Immunoglobulin A Nephropathy

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.